These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25319855)

  • 21. Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study.
    Saito T; Hayakawa M; Kumano O; Honma Y; Murashita M; Kato J; Fukui S; Takahashi M; Takahashi Y; Tsuchida T; Mizugaki A; Takauji S; Hayamizu M; Yoshida T; Katabami K; Wada T; Maekawa K
    J Intensive Care; 2023 Nov; 11(1):54. PubMed ID: 37974289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring heparin anticoagulation in the acute phase response.
    Uprichard J; Manning RA; Laffan MA
    Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
    Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
    Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
    Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
    R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin.
    Mitsuguro M; Okamoto A; Shironouchi Y; Sano M; Miyata S; Neki R; Araki T; Hamamoto T; Yoshimatsu J; Miyata T
    Int J Hematol; 2015 Feb; 101(2):119-25. PubMed ID: 25416968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
    Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
    Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
    Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
    J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidurals in patients receiving thromboprophylaxis with unfractionated heparin three times a day: the value of activated partial thromboplastin time testing.
    Pace M; Koury K; Gulur P
    Anesth Analg; 2014 Nov; 119(5):1215-8. PubMed ID: 25225890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
    Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
    Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
    Bhatt MD; Paes BA; Chan AK
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):605-14. PubMed ID: 26656898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
    Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
    J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort.
    Saini S; Folta AN; Harsh KL; Stanek JR; Dunn AL; O'Brien SH; Kumar R
    J Pediatr; 2019 Jun; 209():212-219.e1. PubMed ID: 30961988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should we abandon the APTT for monitoring unfractionated heparin?
    Arachchillage DRJ; Kamani F; Deplano S; Banya W; Laffan M
    Thromb Res; 2017 Sep; 157():157-161. PubMed ID: 28759760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation.
    Thompson MH; Wilson SH; Toussaint BL; Jordan CL; Hayes GL; McKinzie BP; Wolf BJ; Field LC
    J Clin Anesth; 2016 Sep; 33():346-50. PubMed ID: 27555191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK; Thomson AR; Moriarty HT
    Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols.
    Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C
    Blood; 2015 Oct; 126(18):2091-7. PubMed ID: 26239090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.